References
- Blanpain C, Libert F, Vassart G, Parmentier M. 2002. CCR5 and HIV infection. Receptors Channels 8:19–31.
- Crespi CL. 1995. Xenobiotic-metabolizing human cells as tools for pharmacological and toxicological research. Advances in Drug Research 26:179–235.
- Desai PB, Duan JZ, Zhu YW, Kouzi S. 1998. Human liver microsomal metabolism of paclitaxel and drug interactions. European Journal of Drug Metabolism and Pharmacokinetics 23:417–424.
- Ghosal A, Hapangama N, Yuan Y, Lu X, Horne D, Patrick JE, Zbaida S. 2003. Rapid determination of enzyme activities of recombinant human cytochromes P450, human liver microsomes, and hepatocytes. Biopharmaceutics & Drug Disposition 24:375–384.
- Ghosal A, Satoh H, Thomas PE, Bush E, Moore D. 1996. Inhibition and kinetics of cytochrome P450 3A activity in microsomes from rat, human and cDNA-expressed human cytochrome P450. Drug Metabolism and Disposition: The Biological Fate of Chemicals 24:940–947.
- Heyn H, White RB, Stevens JC. 1996. Catalytic role of cytochrome P4502B6 in the N-demethylation of 5-mephenytoin. Drug Metabolism and Disposition: The Biological Fate of Chemicals 24:948–954.
- Masimirembwa CM, Otter C, Berg M, Jonsson M, Leidvik B, Jonsson E, Johansson T, Backman A, Edlund A, Andersson TB. 1999. Heterologous expression and kinetic characterization of human cytochromes P-450: Validation of a pharmaceutical tool for drug metabolism research. Drug Metabolism and Disposition: The Biological Fate of Chemicals 27:1117–1122.
- Nakajima M, Tane K, Nakamura S, Shimada N, Yamazaki H, Yokoi T. 2002. Evaluation of approach to predict the contribution of multiple cytochrome P450s in drug metabolism using relative activity factor: Effects of the differences in expression levels of NADPH-cytochrome P450 reductase and cytochrome b(5) in the expression system and the differences in the marker activities. Journal of Pharmaceutical Sciences 91:952–963.
- Nelson DR, Koymans L, Kamataki T, Stegeman JJ, Feyereisen R, Waxman DJ, Waterman MR, Gotoh O, Coon MJ, Estabrook RW, Gunsalus IC, Nebert DW. 1996. P450 superfamily: Update on new sequences, gene mapping, accession numbers and nomenclature. Pharmacogenetics 6:1–42.
- Newton DJ, Wang RW, Lu AYH. 1995. Cytochrome P450 inhibitors. Evaluation of specificities in the in vitro metabolism of therapeutic agents by human liver microsomes. Drug Metabolism and Disposition: The Biological Fate of Chemicals 23:154–158.
- Plant NJ, Gibson GG. 2003. Evaluation of the toxicological relevance of CYP3A4 induction. Current Opinion in Drug Discovery & Development 6:50–56.
- Stromer E, Von Moltke LL, Greenblatt DJ. 2000. Scaling drug biotransformation data from cDNA-expressed cytochrome P-450 to human liver: A comparison of relative activity factors and human liver abundance in studies of mirtazapine metabolism. Journal of Pharmacology and Experimental Therapeutics 295:793–801.
- Venkatakrishnan K, Von Moltke LL, Greenblatt DJ. 2001. Application of the relative activity factor approach in scaling from heterologously expressed cytochromes p450 to human liver microsomes: Studies on amitriptyline as a model substrate. The Journal of Pharmacology and Experimental Therapeutics 297:326–337.
- Wrighton SA, Ring BJ. 1994. Inhibition of human CYP3A catalysed l'-hydroxy midazolarn formation by ketoconazole, nifedipine, erythromycin, cimetidine and nizatidine. Pharmaceutical Research 11: 921–924.